BRPI0507629A - composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável - Google Patents
composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitávelInfo
- Publication number
- BRPI0507629A BRPI0507629A BRPI0507629-3A BRPI0507629A BRPI0507629A BR PI0507629 A BRPI0507629 A BR PI0507629A BR PI0507629 A BRPI0507629 A BR PI0507629A BR PI0507629 A BRPI0507629 A BR PI0507629A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- compound
- circulatory
- pharmaceutically acceptable
- therapeutic agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
COMPOSTO, ANTAGONISTA DO RECEPTOR E AGONISTA INVERSO DO RECEPTOR DA HISTAMINA H3, AGENTE PROFILáTICO OU TERAPêUTICO PARA UMA DOENçA METABóLICA, UMA DOENçA CIRCULATóRIA OU UMA DOENçA DO SISTEMA NERVOSO, OU UM SEU SAL FARMACEUTICAMENTE ACEITáVEL Um composto representado pela Fórmula (I): ¢em que Ar representa um grupo divalente formado pela remoção de dois átomos de hidrogênio de benzeno etc.; X¬1¬ representa nitrogênio, enxofre ou oxigênio; R¬1¬ representa heteroarila de 5 ou 6-membros, etc,; o anel A representa heteroarila de 5 ou 6 membros etc.; R¬2¬ e R¬3¬ representam cada um amino, alquilamino etc. e -X¬2¬ representa, p. ex., um grupo representado pela Fórmula (II): (em que R¬4¬ e R¬5¬ representam cada um alquila inferior etc.; e n é um inteiro de 2 a 4)! ou um sal farmaceuticamente aceitável do composto. O composto ou sal tem atividade antagonística contra um receptor da histamina H3 ou atividade agonística inversa contra um receptor da histamina H3 e é útil na prevenção ou tratamento de doenças metabólicas, doenças circulatórias ou doenças neuróticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004037190 | 2004-02-13 | ||
PCT/JP2005/002664 WO2005077905A1 (ja) | 2004-02-13 | 2005-02-14 | 縮環4-オキソ-ピリミジン誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0507629A true BRPI0507629A (pt) | 2007-07-03 |
Family
ID=34836261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0507629-3A BRPI0507629A (pt) | 2004-02-13 | 2005-02-14 | composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável |
Country Status (17)
Country | Link |
---|---|
US (2) | US7521455B2 (pt) |
EP (1) | EP1717230B1 (pt) |
JP (2) | JP4102939B2 (pt) |
KR (1) | KR20070026385A (pt) |
CN (1) | CN1918128B (pt) |
AU (1) | AU2005212092B2 (pt) |
BR (1) | BRPI0507629A (pt) |
CA (1) | CA2555824C (pt) |
EC (1) | ECSP066760A (pt) |
IL (1) | IL177314A0 (pt) |
MA (1) | MA28463B1 (pt) |
NO (1) | NO20064089L (pt) |
NZ (1) | NZ549046A (pt) |
RU (1) | RU2358969C2 (pt) |
UA (1) | UA83416C2 (pt) |
WO (1) | WO2005077905A1 (pt) |
ZA (1) | ZA200606356B (pt) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
CN1918128B (zh) * | 2004-02-13 | 2011-01-26 | 万有制药株式会社 | 稠环4-氧代-嘧啶衍生物 |
CA2569081A1 (en) * | 2004-05-31 | 2005-12-08 | Takashi Mizutani | Quinazoline derivative |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
WO2006068760A2 (en) | 2004-11-19 | 2006-06-29 | The Regents Of The University Of California | Anti-inflammatory pyrazolopyrimidines |
CN101155788A (zh) * | 2005-02-14 | 2008-04-02 | 万有制药株式会社 | 4(3h)-喹唑啉酮衍生物的晶体 |
EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
US8138206B2 (en) | 2005-05-30 | 2012-03-20 | Msd. K.K. | Piperidine derivative |
US20090306375A1 (en) * | 2005-06-07 | 2009-12-10 | Satoshi Kii | Process for production of 4(3H)-quinazolinone derivative |
CN101351459A (zh) * | 2005-07-05 | 2009-01-21 | 万有制药株式会社 | 4(3h)-喹唑啉酮衍生物的制造方法 |
CA2624030A1 (en) | 2005-09-29 | 2007-04-12 | Tianying Jian | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
KR20080094699A (ko) * | 2006-02-15 | 2008-10-23 | 사노피-아벤티스 | 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도 |
MX2008012928A (es) * | 2006-04-04 | 2009-03-06 | Univ California | Antagonistas de pi3-cinasa. |
BRPI0712684A2 (pt) * | 2006-06-08 | 2012-06-19 | Lilly Co Eli | antagonistas do receptor do mch |
US8263772B2 (en) * | 2006-06-08 | 2012-09-11 | Eli Lilly And Company | MCH receptor antagonists |
KR20090024811A (ko) * | 2006-06-23 | 2009-03-09 | 아보트 러보러터리즈 | 히스타민 h3 수용체 조절제로서의 사이클로프로필 아민 유도체 |
US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
CA2663436A1 (en) | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
JP5484914B2 (ja) * | 2007-01-22 | 2014-05-07 | ジーティーエックス・インコーポレイテッド | 核内受容体結合剤 |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
US9623021B2 (en) * | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
CA2682207A1 (en) * | 2007-04-05 | 2008-10-16 | Cv Therapeutics, Inc. | Quinazolinone derivatives as aldh-2 inhibitors |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
US8383657B2 (en) * | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
US20090221648A1 (en) * | 2007-12-21 | 2009-09-03 | Abbott Laboratories | Compositions for treatment of cognitive disorders |
RU2537549C2 (ru) * | 2008-01-04 | 2015-01-10 | Интелликайн ЭлЭлСи | Некоторые химические структуры, композиции и способы |
US8193182B2 (en) * | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
CN101965336B (zh) * | 2008-01-04 | 2015-06-17 | 英特利凯恩有限责任公司 | 某些化学实体、组合物和方法 |
US8993580B2 (en) * | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
WO2009114870A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
WO2009126691A1 (en) * | 2008-04-09 | 2009-10-15 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
CA2730106A1 (en) | 2008-07-08 | 2010-01-14 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
ES2570429T3 (es) | 2008-10-16 | 2016-05-18 | Univ California | Inhibidores de heteroaril quinasa de anillo condensado |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
US8476431B2 (en) * | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
TW201039822A (en) * | 2009-02-06 | 2010-11-16 | Taisho Pharmaceutical Co Ltd | Dihydroquinolinone derivatives |
AU2010234449A1 (en) | 2009-04-07 | 2011-11-03 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
JP2012523424A (ja) | 2009-04-07 | 2012-10-04 | インフイニトイ プハルマセウトイカルス インコーポレイテッド | 脂肪酸アミドヒドロラーゼの阻害薬 |
US9186353B2 (en) * | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
KR101888026B1 (ko) | 2010-02-03 | 2018-08-13 | 인피니티 파마슈티컬스, 인코포레이티드 | 지방산 아미드 하이드롤라제 저해제 |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
CA2806258A1 (en) * | 2010-07-23 | 2012-01-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and application thereof |
WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
DK2663309T3 (en) | 2011-01-10 | 2017-06-19 | Infinity Pharmaceuticals Inc | METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES |
TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
MX2014000648A (es) | 2011-07-19 | 2014-09-25 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y sus usos. |
AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
KR20140075693A (ko) | 2011-08-29 | 2014-06-19 | 인피니티 파마슈티칼스, 인코포레이티드 | 헤테로사이클릭 화합물 및 그의 용도 |
EP2751112B1 (en) | 2011-09-02 | 2019-10-09 | The Regents of The University of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN104995192A (zh) | 2012-09-26 | 2015-10-21 | 加利福尼亚大学董事会 | Ire1的调节 |
BR112015013989A2 (pt) * | 2012-12-27 | 2017-07-11 | Hoffmann La Roche | inibidores de comt |
US9951038B2 (en) | 2012-12-27 | 2018-04-24 | Purdue Pharma L.P. | Quinazolin-4(3H)-one-type piperidine compounds and uses thereof |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
NZ718430A (en) | 2013-10-04 | 2021-12-24 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and uses thereof |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EA201691872A1 (ru) | 2014-03-19 | 2017-04-28 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
RU2719422C2 (ru) | 2014-08-04 | 2020-04-17 | Нуэволюшон А/С | Необязательно конденсированные гетероциклил-замещенные производные пиримидина, пригодные для лечения воспалительных, метаболических, онкологических и аутоиммунных заболеваний |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
WO2016205590A1 (en) | 2015-06-18 | 2016-12-22 | Cephalon, Inc. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
WO2016205633A1 (en) * | 2015-06-18 | 2016-12-22 | Cephalon, Inc. | 1, 4-substituted piperidine derivatives |
US9957267B2 (en) | 2015-07-01 | 2018-05-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
CN114230571A (zh) | 2015-09-14 | 2022-03-25 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
CN113061089A (zh) | 2015-09-23 | 2021-07-02 | 凯瑞康宁生物工程(武汉)有限公司 | γ-羟基丁酸的前药及其组合物和用途 |
DK3362462T3 (da) | 2015-10-12 | 2021-10-11 | Advanced Cell Diagnostics Inc | In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP7054681B2 (ja) | 2016-06-24 | 2022-04-14 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 組合せ療法 |
RU2654062C2 (ru) * | 2016-07-14 | 2018-05-16 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Производные хиназолин-4(3н)-она, ингибирующие натрий-водородный обмен |
CN115025086A (zh) | 2017-03-30 | 2022-09-09 | 凯瑞康宁生物工程(武汉)有限公司 | 双环杂芳基衍生物及其制备与用途 |
EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
JP7308911B2 (ja) * | 2018-09-30 | 2023-07-14 | エックスダブリューファルマ リミテッド | ニューロンヒスタミン受容体-3アンタゴニストとしての化合物およびその使用 |
EP3856719B1 (en) | 2018-09-30 | 2023-06-07 | XWPharma Ltd. | Compounds as neuronal histamine receptor-3 antagonists and uses thereof |
TW202136194A (zh) | 2019-12-20 | 2021-10-01 | 香港商凱瑞康寧有限公司 | 4-纈胺醯氧基丁酸的合成方法 |
CA3160522A1 (en) | 2019-12-20 | 2021-06-24 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
CA3174176A1 (en) | 2020-03-31 | 2021-10-07 | Sanne Schroder Glad | Compounds active towards nuclear receptors |
MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
IL297845A (en) * | 2020-05-04 | 2023-01-01 | Amgen Inc | Heterocyclic compounds as a stimulating receptor expressed in myeloid cells 2 agonists and methods of use |
CN117618393A (zh) | 2020-06-18 | 2024-03-01 | 凯瑞康宁生物工程(武汉)有限公司 | 水溶性活性药物成分的控制释放制粒 |
AU2021293941B2 (en) | 2020-06-18 | 2024-03-28 | XWPharma Ltd. | Pharmaceutical granulations of water-soluble active pharmaceutical ingredients |
WO2022020621A1 (en) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
KR20230058151A (ko) | 2020-10-05 | 2023-05-02 | 엑스더블유파마 리미티드 | 감마-하이드록시부티르산 유도체의 변형된 방출 조성물 |
AU2022238423A1 (en) | 2021-03-19 | 2023-10-19 | XWPharma Ltd. | Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1939109A1 (de) | 1968-08-31 | 1970-03-05 | Troponwerke Dinklage & Co | 2-Methyl-3-[2-(2-diaethylaminoaethoxy)-phenyl]-chinazolinon-(4) und Verfahren zu seiner Herstellung |
GB1583753A (en) * | 1976-07-14 | 1981-02-04 | Science Union & Cie | Piperidine derivatives processes for their preparation and pharmaceutical compositions containing them |
JPS5657768A (en) * | 1979-10-18 | 1981-05-20 | Masayuki Ishikawa | Novel 4-quinazolone derivative substituted by aromatic residue at 3-position |
JPS5665877A (en) * | 1979-11-05 | 1981-06-03 | Masayuki Ishikawa | Preparation of 4-quinazolone derivative |
JPS5651461A (en) * | 1979-10-03 | 1981-05-09 | Masayuki Ishikawa | Novel 3-phenyl-4-quinazolone derivative |
NZ192392A (en) | 1978-12-19 | 1983-02-15 | M Ishikawa | 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones |
US4261996A (en) | 1980-01-11 | 1981-04-14 | Warner-Lambert Company | Pyrazolo[5,1-b]quinazolin-9-(4H)-ones and anti-allergic pharmaceutical compositions containing them |
US4261997A (en) | 1980-01-11 | 1981-04-14 | Warner-Lambert Company | 4-Alkyl-pyrazolo[5,1-b]-quinazolin-9(4H)-ones and anti-allergic compositions containing them |
US4247555A (en) | 1980-01-11 | 1981-01-27 | Warner-Lambert Company | 4,9-Dihydro-9-oxo-N-1H-tetrazol-5-yl-pyrazolo[5,1-b]-quinazoline-2-carboxamides and antiallergic compositions and methods using them |
JPS57118570A (en) * | 1981-01-16 | 1982-07-23 | Masayuki Ishikawa | Novel 3-phenyl-4-quinazolone derivative |
AU543928B2 (en) | 1981-01-16 | 1985-05-09 | Masayuki Ishikawa | 4(311)-quinazolinone derivatives |
US5948775A (en) | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
ES2788383T3 (es) | 2000-04-25 | 2020-10-21 | Icos Corp | Inhibidores de delta fosfatidilo-inositol 3-quinasa humana |
GB0124627D0 (en) * | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
US7285557B2 (en) | 2001-10-15 | 2007-10-23 | Smithkline Beecham P.L.C. | Pyrimidinones as melanin concentrating hormone receptor 1 |
US7220777B2 (en) | 2001-10-15 | 2007-05-22 | Smithkline Beecham P.L.C. | Lactam derivatives as antagonists for human 11cby receptors |
CN1918128B (zh) * | 2004-02-13 | 2011-01-26 | 万有制药株式会社 | 稠环4-氧代-嘧啶衍生物 |
CA2569081A1 (en) * | 2004-05-31 | 2005-12-08 | Takashi Mizutani | Quinazoline derivative |
CN101155788A (zh) | 2005-02-14 | 2008-04-02 | 万有制药株式会社 | 4(3h)-喹唑啉酮衍生物的晶体 |
CN101351459A (zh) | 2005-07-05 | 2009-01-21 | 万有制药株式会社 | 4(3h)-喹唑啉酮衍生物的制造方法 |
-
2005
- 2005-02-14 CN CN2005800049394A patent/CN1918128B/zh not_active Expired - Fee Related
- 2005-02-14 KR KR1020067016304A patent/KR20070026385A/ko not_active Application Discontinuation
- 2005-02-14 US US11/058,444 patent/US7521455B2/en active Active
- 2005-02-14 NZ NZ549046A patent/NZ549046A/en unknown
- 2005-02-14 UA UAA200609795A patent/UA83416C2/uk unknown
- 2005-02-14 EP EP05710446.5A patent/EP1717230B1/en active Active
- 2005-02-14 JP JP2005518071A patent/JP4102939B2/ja not_active Expired - Fee Related
- 2005-02-14 RU RU2006132729/04A patent/RU2358969C2/ru not_active IP Right Cessation
- 2005-02-14 WO PCT/JP2005/002664 patent/WO2005077905A1/ja active Application Filing
- 2005-02-14 BR BRPI0507629-3A patent/BRPI0507629A/pt not_active IP Right Cessation
- 2005-02-14 CA CA2555824A patent/CA2555824C/en active Active
- 2005-02-14 AU AU2005212092A patent/AU2005212092B2/en active Active
-
2006
- 2006-08-01 ZA ZA200606356A patent/ZA200606356B/xx unknown
- 2006-08-06 IL IL177314A patent/IL177314A0/en unknown
- 2006-08-09 EC EC2006006760A patent/ECSP066760A/es unknown
- 2006-09-11 MA MA29313A patent/MA28463B1/fr unknown
- 2006-09-12 NO NO20064089A patent/NO20064089L/no not_active Application Discontinuation
-
2007
- 2007-12-27 JP JP2007335972A patent/JP2008156358A/ja active Pending
-
2009
- 2009-02-11 US US12/378,163 patent/US8268842B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ZA200606356B (en) | 2008-07-30 |
EP1717230A1 (en) | 2006-11-02 |
UA83416C2 (en) | 2008-07-10 |
EP1717230A4 (en) | 2009-09-23 |
JP2008156358A (ja) | 2008-07-10 |
EP1717230B1 (en) | 2014-08-06 |
RU2006132729A (ru) | 2008-03-20 |
WO2005077905A1 (ja) | 2005-08-25 |
CN1918128A (zh) | 2007-02-21 |
ECSP066760A (es) | 2006-11-16 |
RU2358969C2 (ru) | 2009-06-20 |
IL177314A0 (en) | 2006-12-10 |
CA2555824C (en) | 2011-06-07 |
AU2005212092A1 (en) | 2005-08-25 |
JP4102939B2 (ja) | 2008-06-18 |
MA28463B1 (fr) | 2007-03-01 |
US20090209562A1 (en) | 2009-08-20 |
NZ549046A (en) | 2010-06-25 |
US7521455B2 (en) | 2009-04-21 |
KR20070026385A (ko) | 2007-03-08 |
CA2555824A1 (en) | 2005-08-25 |
US20050182045A1 (en) | 2005-08-18 |
CN1918128B (zh) | 2011-01-26 |
AU2005212092B2 (en) | 2011-01-20 |
JPWO2005077905A1 (ja) | 2007-10-18 |
NO20064089L (no) | 2006-11-06 |
US8268842B2 (en) | 2012-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507629A (pt) | composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável | |
RU2207341C2 (ru) | Новые циклические соединения диамина, содержащие их лекарственные средства и способы лечения | |
BRPI0512985A (pt) | derivados de 3-carbamoil-2-piridona | |
BRPI0616574A2 (pt) | derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2 | |
BRPI0418082B8 (pt) | derivados de tiazol úteis como antagonistas de receptor de adenosina a2a | |
BR0113448A (pt) | Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase | |
BR0311806A (pt) | Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso | |
DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
BR0315815A (pt) | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto | |
BRPI0608216A2 (pt) | agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo | |
BRPI0407618A (pt) | derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização | |
CY1109624T1 (el) | Υποκατεστημενα παραγωγα θειοφαινιου ως ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις | |
ATE412647T1 (de) | Substituierte n-arylpyrrolidine als selektive modulatoren des androgenrezeptors | |
BRPI0512916A (pt) | derivado de tienopirazol tendo atividade inibidora de pde 7 | |
HRP20090627T1 (hr) | Inhibitori hcv ns3 proteaze | |
BR0212893A (pt) | Derivados de 4-pirimidona-3-substituìdo | |
BRPI0511504A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides | |
EP1775283A4 (en) | 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1) | |
BR0012697A (pt) | Inibidores da diferenciação de th2 | |
MX2021006265A (es) | Derivados de panteteina y usos de los mismos. | |
BR0112582A (pt) | Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos | |
RS52044B (en) | USE OF BENZO-CONDENSED HETEROCYCLIC SULFAMIDES DERIVATIVES FOR OBESITY TREATMENT | |
BRPI0418074B8 (pt) | derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos | |
BRPI0407097A (pt) | Antagonista do casr | |
DK1781299T3 (da) | Anti-inflammatoriske midler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: MSD K.K. (JP) Free format text: TRANSFERIDO DE: BANYU PHARMACEUTICAL CO., LTD. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015. |